Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mage-a3-immtac
- Development stage
- Discontinued
- Lead developer
- Immunocore
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MAGE-A3-ImmTAC (also known as IMC-A121) is a first-generation bispecific T-cell engager developed by Immunocore using its proprietary ImmTAC (Immune-mobilizing monoclonal TCRs Against Cancer) platform. The molecule is a recombinant fusion protein comprising a soluble, affinity-matured T-cell receptor (TCR) specific for a MAGE-A3 peptide (presented by HLA-A*01) fused to an anti-CD3 single-chain antibody fragment (scFv). Its mechanism of action involves the TCR domain binding to MAGE-A3-positive cancer cells, while the anti-CD3 domain recruits and activates polyclonal T cells to induce tumor cell lysis. MAGE-A3 is a cancer-testis antigen expressed in various malignancies, including melanoma and non-small cell lung cancer, but not in normal tissues. Clinical development of MAGE-A3-ImmTAC was terminated following early-phase trials.
- Other names
- MAGE-A3 ImmTACMAGE-A-3 ImmTACMAGE-A 3 ImmTAC
02
Targets
CD3 (T-cell surface glycoprotein CD3)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on mage-a3-immtac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mage-a3-immtac.